CA2338093C - Vaccins contre l'infection due a l'escherichia coli o157 - Google Patents

Vaccins contre l'infection due a l'escherichia coli o157 Download PDF

Info

Publication number
CA2338093C
CA2338093C CA2338093A CA2338093A CA2338093C CA 2338093 C CA2338093 C CA 2338093C CA 2338093 A CA2338093 A CA 2338093A CA 2338093 A CA2338093 A CA 2338093A CA 2338093 C CA2338093 C CA 2338093C
Authority
CA
Canada
Prior art keywords
coli
antibodies
conjugates
lps
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2338093A
Other languages
English (en)
Other versions
CA2338093A1 (fr
Inventor
Shousun C. Szu
John B. Robbins
Edward Konadu (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CA2714833A priority Critical patent/CA2714833A1/fr
Priority to CA2338093A priority patent/CA2338093C/fr
Publication of CA2338093A1 publication Critical patent/CA2338093A1/fr
Application granted granted Critical
Publication of CA2338093C publication Critical patent/CA2338093C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Conjugués du polysaccharide à spécificité O de E. coli O157 avec un véhicule, et compositions à base desdits conjugués, procédés d'utilisation de ces conjugués et/ou compositions pour induire une réponse immunogène chez des mammifères, dont des réponses qui fournissent une protection contre des infections bactériennes ou en réduisent la gravité. La présente invention concerne plus particulièrement l'utilisation de polysaccharides contenant l'unité de répétition tétrasaccharide (?3)-.alpha.-D-GalpNAc-(1?2)-.alpha.-D-PerpNAc-(1?3)-.alpha.-L-Fucp-(1?4)-.beta.-D-Glcp-(1?) et de conjugués de ladite unité pour la production d'anticorps sériques ayant une activité bactéricide (tueuse) contre E. coli provoquant le syndrome de Gasser, en particulier E. coli O157. Lesdits conjugués et les compositions les contenant sont utiles en tant que vaccins destinés à produire des anticorps sériques qui ont une activité bactéricide ou bactériostatique contre E. coli, en particulier contre E. coli O157, et sont utiles pour prévenir et/ou traiter des maladies provoquées par E. coli O157. La présente invention concerne en outre des anticorps qui présentent une réaction immunitaire contre le polysaccharide à spécificité O de E. coli O157 et/ou le véhicule et qui sont induits par ces conjugués et/ou compositions. Elle concerne encore des procédés et des kits reposant sur l'utilisation d'un ou plusieurs des polysaccharides, conjugués ou anticorps décrits ci-dessus.
CA2338093A 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157 Expired - Fee Related CA2338093C (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2714833A CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157
CA2338093A CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1998/014976 WO2000004922A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157
CA2338093A CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2714833A Division CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Publications (2)

Publication Number Publication Date
CA2338093A1 CA2338093A1 (fr) 2000-02-03
CA2338093C true CA2338093C (fr) 2010-11-30

Family

ID=22267510

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2714833A Abandoned CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157
CA2338093A Expired - Fee Related CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2714833A Abandoned CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Country Status (4)

Country Link
AU (1) AU767047B2 (fr)
BR (1) BR9815953A (fr)
CA (2) CA2714833A1 (fr)
WO (1) WO2000004922A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
KR101947794B1 (ko) 2006-03-17 2019-02-13 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
NZ249704A (en) * 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
ATE254475T1 (de) * 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten

Also Published As

Publication number Publication date
CA2338093A1 (fr) 2000-02-03
AU8575898A (en) 2000-02-14
WO2000004922A1 (fr) 2000-02-03
CA2714833A1 (fr) 2000-02-03
BR9815953A (pt) 2001-03-06
AU767047B2 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
US8168195B2 (en) Vaccines against Escherichia coli O157 infection
Alexander et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses
CN108430500B (zh) 用于针对肠外致病性大肠杆菌的免疫保护的方法和组合物
AU669854B2 (en) Escherichia coli O-polysaccharide-protein conjugate vaccine
ES2200067T3 (es) Fragmentos de polisacaridos antigenicos de tipo ii y tipo iii de streptococcus del grupo b, que tienen una estructura terminal 2,5-anhidro-d-manosa, y su vacuna conjugada.
WO2000033882A1 (fr) Conjugue vaccinal vi-repa pour l'immunisation contre la salmonella typhi
IE913399A1 (en) Improved oligosaccharide conjugate vaccines
US8202520B2 (en) Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
Pawlowski et al. Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
US9173932B2 (en) Vibrio cholerae O139 conjugate vaccines
CA2338093C (fr) Vaccins contre l'infection due a l'escherichia coli o157
Wu et al. Investigation of nontypeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines
Liao et al. Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi
Szu et al. Vaccines for prevention of enteric bacterial infections caused by Salmonellae
Schneerson et al. VACCINES FOR PREVENTION OF ENTERIC BACTERIAL INFECTIONS CAUSED BY SALMONELLAE

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170720